256 related articles for article (PubMed ID: 29478674)
1. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
3. Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation.
Tanihara F; Hirata M; Nguyen NT; Le QA; Hirano T; Takemoto T; Nakai M; Fuchimoto DI; Otoi T
PLoS One; 2018; 13(10):e0206360. PubMed ID: 30352075
[TBL] [Abstract][Full Text] [Related]
4. Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research.
Eun K; Park MG; Jeong YW; Jeong YI; Hyun SH; Hwang WS; Kim SH; Kim H
BMC Biotechnol; 2019 Jan; 19(1):1. PubMed ID: 30606176
[TBL] [Abstract][Full Text] [Related]
5. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
Zhang X; Wang L; Liu M; Li D
Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 therapies in experimental mouse models of cancer.
Estêvão D; Rios Costa N; da Costa RG; Medeiros R
Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 as a Tool in Cancer Therapy.
Zatloukalová P; Krejčíř R; Valík D; Vojtěšek B
Klin Onkol; 2019; 32(Supplementum 3):13-18. PubMed ID: 31627701
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
11. Counterpoint: The Potential Harms of Human Gene Editing Using CRISPR-Cas9.
Baylis F
Clin Chem; 2018 Mar; 64(3):489-491. PubMed ID: 29490999
[No Abstract] [Full Text] [Related]
12. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
Kuruvilla J; Sasmita AO; Ling APK
Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
[TBL] [Abstract][Full Text] [Related]
13. Editor's comment on "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein".
Hohmann S
Mol Genet Genomics; 2017 Jun; 292(3):535-536. PubMed ID: 28251316
[No Abstract] [Full Text] [Related]
14. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
15. Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer.
Jiang C; Lin X; Zhao Z
Trends Mol Med; 2019 Nov; 25(11):1039-1049. PubMed ID: 31422862
[TBL] [Abstract][Full Text] [Related]
16. Surprising CRISPR roadblocks.
Rusk N
Nat Methods; 2018 Aug; 15(8):569. PubMed ID: 30065373
[No Abstract] [Full Text] [Related]
17. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
18. Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects.
Zheng G; Zhu Q; Dong J; Lin X; Zhu C
BMC Biotechnol; 2019 Nov; 19(1):74. PubMed ID: 31703569
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
20. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.
Yin H; Xue W; Chen S; Bogorad RL; Benedetti E; Grompe M; Koteliansky V; Sharp PA; Jacks T; Anderson DG
Nat Biotechnol; 2014 Jun; 32(6):551-3. PubMed ID: 24681508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
